Haemorrhage as a cause of maternal deaths in developing countries and the relationship to the availability of blood for transfusion : 1
The impact of changes in anti-RhD immunoglobulin manufacture on the frequency of neonatal Coombs test positivity : 2
Use of Scottish National Blood Transfusion Service (SNBTS) methylene blue treated, removed fresh frozen plasma and cryoprecipitate in a regional neonatal unit : 3
Hospital blood transfusion services in a mass casualty situation : lessons to be learned from July 2005 London bombings
Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group) : 5
Six-colour flow cytometry improves the detection of circulating lymphoma cells : 6
Interim report of the UKCLL02 Trial : a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials Sub-Group)
Management and outcome of 200 cases of feto-maternal alloimmune thrombocytopenia and lack of association between HPA-1a antibody potency and bioactivity and severity of disease : 8
Stem cell transplantation and cord blood processing quality control using a non-subjective, fully standardised colony-forming proliferation assay : 9
Peripheral blood stem cell harvesting using a COBE Spectra : a comparison of 2 collect rates on product quality
Phase II prospective study of extracorporeal phototherapy for the treatment of refractory chronic extensive graft-versus-host disease performed in Newcastle Upon Tyne : 11
Screening CML for genetic imbalances by array CGH : 12
Pathogenic anti-beta2-glycoprotein I antibodies recognise domain I of beta2-glycoprotein I only after an anionic surface-induced conformational change : 13
Amino acid regions 572-579 and 657-666 of the spacer domain provide a common antigenic core required for binding of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura : 14
Disappearance of IgG antibody to ADAMTS 13 following rituximab in acute refractory thrombotic thrombocytopenic purpura : 15
Prescription of low molecular weight heparin (LMWH) for prophylaxis against venous thromboembolism (VTE) in medical patients : 145
Acceptability of patient self-testing/self-management of oral anticoagulation in new patients : 146
TPE or not to TPE : that is the question
Rapid infusion of Rituximab can be given safely and has a significant impact on capacity : 148
Establishing a hospital based, nurse led clinic for myeloproliferative disorders : 149
A comprehensive approach to chemotherapy record keeping : 150
A role for direct nursing input into the Serious Hazards of Transfusion Scheme : 151
Protein S stimulates inhibition of the factor VIIa/tissue factor pathway by tissue factor pathway inhibitor (TFPI) : 152
Fibrin bound thrombin is pivotal in the initiation of the thrombin burst and is a key determinant of the amplification phase of clot formation : 153
The Plasma Kallikrein–Kinin System and its predictive role in coronary heart disease and ischaemic stroke; follow up from the Second Northwick Park Heart Study : 154
Proteolytic regulation of factor XIII activity by plasmin : A novel mechanism for the regulation of clot formation
Downregulation of low density lipoprotein-induced platelet signalling : 156
Microparticle-associated endothelial protein C receptor can potentiate the anti-apoptotic and cytoprotective function of activated protein C : 157
Hyperglycaemia and the risk of arterial thrombosis : studies in mice
The potential of using gene expression data to identify patients that are likely to respond to molecular therapies : 159
Lack of correlation of clonality status with the level of Val617Phe JAK2 mutant in essential thrombo-cythaemia (ET) indicates that the JAK2 mutation, when present, is not the primary pathogenic event : 160
BCR-ABL activity assessed by P-CrkL flow cytometry may predict improved in vivo response to dasatinib versus IM : 161
Low-dose imatinib therapy leads to rapid induction of major molecular responses with achievement of molecular remission in FIP 1L1 -PDGFRA associated hypereosinophilic syndrome : 162
Reduced intensity allogeneic stem cell transplantation in patients with myelofibrosis : 163
CCN3 expression reduces the clonogenic potential and growth of BCR-ABL1cells : 164
Use of pre-emptive donor lymphocyte infusions to achieve durable remission following alemtuzumab based reduced intensity conditioning (RIC) transplantation for AML or MDS : 165
A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation : 166
The role of family history in idiopathic venous thrombosis : 167
Associations between oxyhaemoglobin desaturation and haematology in African children with sickle cell anaemia : 168
Long term stability of red cell responses in patients with paroxysmal nocturnal haemoglobinuria (PNH) on eculizumab therapy : implications for the future treatment and management of PNH
A novel mutation in the HIF prolyl hydroxylase, PHD2, associated with familial erythrocytosis : 170
Air pollution levels impact on numbers of hospital admissions with acute vaso-occlusive sickle cell pain : 171
Glycocalyx perturbation in patients with sickle cell disease : implications for vascular vulnerability
MRI T2 * measurements show no myocardial iron loading in multi-transfused low-risk MDS patients : 173
Expression of human FIX at therapeutic levels in nonhuman primates following a single peripheral vein infusion of low doses of self complementary AAV vector renews hope for haemophilia B gene therapy : 174
Treatment characteristics and the risk of inhibitor development : a multi-centre cohort study among previously untreated patients with severe haemophilia A
Increased O-linked glycosylation of von Willebrand factor in patients with von Willebrand disease type 1 : 176
A novel inherited form of familial thrombocytopenia due to an autosomal dominant mutation in the cytoplasmic domain of the platelet beta3 integrin that is associated with the expression of activation dependent alphaIIb/beta3 epitopes : 177
The Nijmegen Haemostasis Assay : a tool to study the interplay between coagulation and fibrinolysis
The natural history of hepatitis C in patients with bleeding disorders : 179
Genome wide linkage analysis of von Willebrand factor antigen levels : 323
Secretion and clearance of von Willebrand factor and the risk of venous thrombosis : 324
No evidence of significant FANCF, FANCB or NBS1 methylation in sporadic acute childhood leukaemia : 325
Low level expression of BCR-ABL (p190) in Philadelphia negative paediatric acute lymphoblastic leukaemia presents difficulties with diagnosis and with monitoring of minimal residual disease : 326
EVI1 amplification and over-expression in FA-derived AML cell lines with bi-allelic FANCD1/BRCA2 mutations : 327
Cytotoxicity assays to support the diagnosis of haemophagocytic syndromes : 328
Characterisation of the biochemical and genetic defect in congenital glycosylphosphatidylinositol (GPI) deficiency : 329
Rituximab in children with immune deficiency states complicated by autoimmune thrombocytopenia : 330
Anticoagulants inhibit tumour metastasis independent of fibrin formation : 331
Outpatient management of pulmonary embolism : results from the National Multicentre PE Study
Active site inhibited factor VIIa reduces myocardial infarct size after ischaemia/reperfusion injury in mice via tissue factor/NFkappaB-mediated mechanisms : 333
Mutations in VKORC 1 are associated with pharmaco-dynamic resistance to warfarin : 334
Novel transmembrane megakaryocyte proteins identified by comparative gene expression profiling of in vitro differentiated human megakaryocytes and erythroblasts : 335
In situ gene expression profiling and quantitation using quantum dot based multiplex hybridisation in clinical samples : 336
HOXB4 overexpression promotes haematopoietic development by human embryonic stem cells : 337
Cytoplasmic function of mutant PML and PML-RARalpha : 338
Endolyn, a novel modulator of CXCR4-driven migration : 339
Role of the Wnt/GSK3/beta catenin pathway during haemopoietic development and chronic myelomono-cytic leukaemia : 340
Coordinated actions of PSGL-1 and beta2-integrins mediate adhesion of leucocytes to von Willebrand factor : 16
Impaired ribosomal biogenesis affecting non-erythroid cells in both RPS19-mutated and non-mutated Diamond Blackfan Anaemia : 17
Differentially expressed genes in erythroid and non-small cell lung carcinoma cells identified by suppression subtractive hybridisation : 18
Comparative specificity of the proteasome inhibitors BzLLLCOCHO, PS-341 and MG-132 : 19
The preponderence of Hoxa6 expression in haemo-poietic cells : 20
Selective migration of IgVH31 B-cell chronic lymphocytic leukaemia clones in response to chemokine SDF1 : 21
Dual functionality of erythropoietin detected using a colony-forming proliferation assay : 22
NF Kappa B as a therapeutic target in AML : 23
Microarray analysis points towards C/EBPdelta as a novel mediator in endotoxin-induced DIC : 24
Developing proteasome assays for clinical studies : 25
Mutations in the reverse transcriptase component of telomerase : their impact on telomere length and bone marrow failure
Global gene expression profiling in patients diagnosed with idiopathic thrombocytopenia (ITP) using affymetrix gene expression arrays : 27
The JAK2 V617F mutation in the myeloproliferative disorders : 28
Recombinant platelet derived growth factor (rPDGF) in the treatment of ulcerated necrobiosis lipoidica (NL) : 29
Reversal of apoptosis resistance and erythropoietin independent growth of primary erythroid progenitors from patients with polycythaemia vera (PV) by inhibitors of the Jak2 tyrosine kinase : 30
The use of a molecular-based technique for the identification of G6PD deficiency in jaundiced neonates as compared to the fluorescent-spot assay : 31
Haemophagocytic lymphohistiocytosis (HLH) following orthotopic liver transplantation : a single centre report of 37 cases
High response rates to erythropoietin therapy for chemotherapy-associated anaemia using targeted intravenous iron supplementation : 33
Prevalence of the JAK2 tyrosine kinase mutation in patients with an established diagnosis of myeloproliferative disease : 34
Thalassaemia major : on the verge of bleeding or thrombosis?
Anaemia in pregnancy at the Royal London Hospital : 36
The need for a quality assessment scheme for serum erythropoietin kits : 37
Progressive multifocal leucoencephalopathy (PML) following Rituximab-combination chemotherapy treatment : 38
Outcome and management of 3 pregnancies in patients with idiopathic myelofibrosis : 39
Can splenectomy abolish the ADAMTS-13 inhibitor in a patient with chronic relapsing thrombotic thrombocytopenic purpura (TTP)? : 40
Haptoglobin and severe pain crisis in sickle cell anaemia patients : 41
Audit of indications for out of hours coagulation screening at the Ulster Hospital : 42
An interactive navigation tool to promote recruitment to health care science in haematology in school students between 14-19 years old : 43
A comparative pharmacodynamic study of anti-Xa activity to evaluate the accumulation effect of tinzaparin and enoxaparin given at prophylactic dose over 8 days in medical elderly patients with impaired renal function : 44
Reversal of asymptomatic over-anticoagulation in an outpatient setting : 45
Coagulating plasma rapidly induces IL-8 production by human lung epithelial cells : 46
INR control following oral vitamin K for reversal of asymptomatic over-anticoagulation with warfarin : 47
Use of prothrombin concentrate (PCC) for warfarin reversal : audit of North Thames practice
An evaluation of HemoSense™ INRatio prothrombin time monitoring system : 49
Factor VIII concentration and thrombin generation determination : 50
A comparative half life study using global measures of haemostasis in a patient with severe haemophilia A complicated by an inhibitor : differing responses to recombinant FVIII and plasma derived FVIII
Two novel mutations in factor VII deficiency : 52
Five novel candidate mutations in type 2A, 2M and 2N von Willebrand disease patients from the west of Scotland : 53
Poor correlation in thrombin generation estimation between ROTEM thromboelastometry and the fluorogenic thrombogram in normal subjects : 54
Treatment of acquired von Willebrand syndrome : comparison of two different intermediate-purity factor VIII concentrates
Can lyophilised plasma be used as quality control material for the TEG analyser? : 56
A candidate mechanism for von Willebrand factor abnormalities in a patient with acquired von Willebrand syndrome : 57
Lymphoproliferative disease associated with strong lupus anticoagulant directed against multiple clotting factors : 58
Platelet adhesion to dimeric beta2-glycoprotein-I under conditions of flow is mediated by glycoprotein Ibalfa and ApoER2' : 59
The effect of flight-related behaviour on the risk of venous thrombosis after air travel : 60
HLA associated with susceptibility to idiopathic thrombotic thrombocytopenic purpura : further evidence for an immunogenetic link?
Modulation of prothrombin-induced APC resistance by protein S levels : 62
Coagulation activation and antiphospholipid antibodies (APA) in a large cohort of subjects with myeloproliferative disease (MPD) : 63
Genetic variation in ADP-receptor P2Y12 and the risk of arterial thrombosis : 64
Intermittent mechanical calf compression for prevention of travellers' thrombosis : 65
Assay of fibrin/fibrinogen degradation products specific to the enzyme that is responsible for the degradation, offers improved diagnostic possibilities : 66
High VWF levels increase the relative risk of first ischaemic stroke : influence of ADAMTS13, inflammation and genetic variation
Venous thromboembolism, cancer and survival : findings from a prospective outpatient treatment registry (VERITY)
Five fold increase in risk of venous thrombosis after minor injury in the leg : 69
Laboratory D-dimer measurement in the exclusion of DVT : any nearer agreement?
Increased platelet activation after major vascular surgery despite aspirin therapy : 71
Increased procoagulant platelet-derived microparticles in patients with essential thrombocythaemia : 72
ADAMTS13 antigen levels in ± TTP patients studied longitudinally : 73
Thrombin activatable fibrinolysis inhibitor (TAFI) affects the fibrinolytic potential of different plasminogen activators in an external plasma clot lysis model : 74
GPVI deficiency associated with unexpected severe bleeding in a 33-year-old patient with moderate thrombocytopenia and autoantibodies against the GPVI-Ig-like domains : 75
High altitude exposure causes a reduction in PFA-100™ closure time in humans : evidence of platelet activation or a result of increased haematocrit?
Retrospective audit of thrombophilia screening in a UK district general hospital : 77
Monitoring endogenous thrombin generation in healthy individuals and patients after a first acute myocardial infarction : 78
Interpretation of normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant : 79
Utility and cost of heritable thrombophilia screening : a clinical audit
ABO blood groups in cerebrovascular accident patients : 81
The use of the PFA-100 and thromboelastograph in assessing drug efficacy and haemostasis in essential thrombocythaemia : 82
A prospective audit of MDA D-dimer assay in patients with suspected deep vein thrombosis : 83
Molecular monitoring of minimal residual disease in adult ALL, the UKALL12 trial experience : 84
Applicability of large scale interphase FISH screening in the diagnosis and prognosis of multiple myeloma : 85
High incidence of myelodysplasia and secondary leukaemia in the UK MRC pilot study of autografting in chronic lymphocytic leukaemia : 86
Generation of reactive oxygen species by parthenolide rapidly and selectively induces apoptosis of B-chronic lymphocytic leukaemia (CLL) cells via a p53 independent pathway : 87
Minimal residual disease monitoring of BCR-ABL+ adult acute lymphoblastic leukaemia using quantitative real-time PCR : preliminary results from the UKALLXII trial
High incidence of therapy-related myelodysplasia and acute myeloid leukaemia (tMDS/tAML) following treatment with fludarabine and cyclophosphamide for low grade lymphoproliferative disorders : 89
CD38+ sub-clones exhibit a distinct transcription and protein expression signature when compared with CD38- sub-clones derived from the same CLL patient : 90
Prognostic factors in the UK LRF CLL4 trial : 91
Drug cross-resistance by TRAC assay of untreated patients in the UK LRF CLL4 trial : 92
Single-tube six-colour flow cytometry screening assay for paraprotein-associated B-cell and plasma cell disorders : 93
CDR3 sequence homology in mutated and unmutated chronic lymphocytic leukaemia : 94
A comparison of oral and intravenous fludarabine in the LRF CLL4 Trial (on behalf of the UK NCRI CLL Trials Group) : 95
Clinical effect of Imatinib following remission induction in adult Philadelphia chromosome-positive acute lymphoblastic leukaemia : early results from the MRC UKALL12 Study
Cyclooxygenase-2 (COX-2) expression is more in plasma cells from patients with clonal plasmacytosis : 97
Removal of serum free light chains by haemodialysis in patients with multiple myeloma : 98
Anthracycline-based chemotherapy as first-line treatment in adults with malignant post transplant lymphoproliferative disorder (PTLD) after solid organ transplantation : 99
B-cell antigen expression in t(11;14) myeloma : a potential diagnostic pitfall
Investigation of lymphoproliferative disorders in Ghana, West Africa : 101
Acute childhood leukaemias and exposure to electromagnetic fields generated by very high voltage power lines : 102
Hypoglycaemia due to an IgA-insulin binding antibody in a patient with IgA kappa myeloma : 103
Is Rituximab administration a risk factor for Pneumocystis pneumonia? : 104
HIV associated Hodgkin's Lymphoma : improved outcome within a single centre
Are trucut biopsies as effective as surgical excisions in diagnosing lymphomas? A DGH experience : 106
Re-challenging myeloma patients with bortezomib : experience at a single centre
Bone marrow fibrosis is not a predictor of overall survival in patients with myeloma : 108
Intravascular large B-cell lymphoma : distinct entity or mode of transformation/progression in other lymphoproliferative disorders?
Tolerability of fludarabine-based chemotherapies : 110
Early and sustained response to azacitidine occurs in high-risk MDS patients with monosomy 7 : responses correlate with increased apoptosis not CDKN2B demethylation
Single agent cloretazine is an effective induction therapy in elderly patients (pts) with poor risk AML : 112
Gene expression profiling can identify novel MRD markers for AML : 113
Therapeutic efficacy of interferon-beta in a xenograft model of acute myeloid leukaemia : 114
hTERT expression in AML is heterogeneous and is of likely prognostic significance : 115
Evaluation of three diagnostic criteria for polycythaemia vera : 116
A multi-centre and multi-national programme to assess the clinical accuracy of the molecular sub-classification of leukaemia by gene expression profiling : 117
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with relapsed AML following a short initial complete remission : 118
Acute promyelocytic leukaemia in India : is it different from the West
Acute myeloid leukaemia presenting with mediastinal myeloid sarcoma : a single institution experience
Polysomy 8 in CML : 121
Outcomes in good risk AML with additional adverse chromosomal abnormalities : 122
An audit on AML patients in a district general hospital : Patient characteristics
Acute panmyelosis with myelofibrosis : 124
Results of alemtuzumab-based reduced-intensity allogeneic transplantation for advanced chronic lymphocytic leukaemia : a BSBMT study
Reduced intensity conditioned volunteer unrelated donor transplants using alemtuzumab are safe and effective in older patients with myelodysplastic syndromes : 126
Improved outcome following reduced intensity conditioned allogeneic haematopoietic stem cell transplantation compared with myeloablative conditioning for acute myeloid leukaemia : 127
Identification and characterisation of a CD4Hi lymphocyte subpopulation displaying a predominant central memory phenotype : a kinetic study of allo-reactive lymphocytes LK MARLES and G COOK
Outcomes of patients with AML and poor risk MDS following non-myeloablative conditioning with 50 mg versus 100mg alemtuzumab : 129
Use of autologous bone marrow harvests (BMH) in patients undergoing volunteer unrelated donor stem cell transplantation : a single centre experience
The effect of extracorporeal photopheresis on pro-inflammatory cytokine production in different T cell subsets : 131
Photopheresis at the Belfast City Hospital : 132
GCSF mobilisation in patients with idiopathic myelofibrosis : 133
Early mortality outcome of allogeneic stem cell transplants performed in non HEPA-filter rooms in India : 134
A decade of haemovigilance : influencing transfusion safety
The uptake of routine antenatal anti-D prophylaxis within north Bristol : 136
NHS Scotland Blood Traceability System : 137
Expression of NADH-cytochrome b 5 reductase variants provides important functional insights into recessive congenital methaemoglobinaemia : 138
Prospective screening of patients with sickle cell disease for the presence of pulmonary arterial hypertension as determined by tricuspid regurgitant jet velocity at echocardiography : 139
Evaluation of electrospray MSMS for the detection of thalassaemia : 140
Beta-thalassaemia mutations in the Northern Ireland population : 141
Alloimmunisation rate in sickle cell disease : 142
Mapping the central Manchester population at risk from haemoglobinopathies : 143
Erythropoietin estimation in health and disease using a new automated assay : 144
Coagulation factor Xa drives tumour cells into apoptosis through BH3-only protein Bim upregulation : 180
Blueprint of the response of CD133+ and bone marrow stromal cells to hypoxia : 181
Activated protein C inhibits neutrophil migration by Rho/Src dependent Limk1 phosphorylation : 182
Erythroid versus non-erythroid erythropoietin receptor expression and function : 183
Increased regulatory T cell subsets (TReg and Tr1 cells) in the peripheral blood of patients with multiple myeloma correlate with disease stage : 184
Stem cells in V617F JAK2 associated polycythaemia rubra vera (PRV) differentiate less than once per two yearly and generate 3-4.1012 red cells over 16-17 months : 185
Structural models of the snake venom factor V activators from Daboia russelli and Daboia lebetina : 186
Genetic heterogeneity exists in autosomal recessive Dyskeratosis congenita : 187
Optimisation of a robust methodology for the identification of JAK2 mutations in patients with myeloproliferative disorders : 188
Development of a quantitative real-time PCR assay for the detection of the JAK2 V617F mutation in myeloproliferative disorders : 189
Cytokine stimulation increases proteasome activity : 190
Functional analysis of a novel prothrombin variant, C20209T, which is relatively prevalent among black Americans : 191
The effect of coronary angiography and percutaneous intervention on total white cell counts and differential counts in patients with chronic stable angina : part of a systemic inflammatory response?
Recombinant human erythropoietin stimulates endothelial progenitor cell mobilisation in patients with chronic renal failure : implications for prevention of atherosclerotic complications
Primary erythroblasts from patients with polycythaemia vera (PV) have a distinct gene expression signature from both idiopathic erythrocytosis (IE) and normal controls which shows limited changes in Jak-STAT target genes : 194
Correlation of JAK2 V617F mutation status with clonality in patients with polycythaemia rubra vera (PRV) and essential thrombocythaemia (ET) : 195
A fixed, low dose of anti-CD20 antibody (Rituximab) is an effective treatment for patients with chronic immune thrombocytopenia : 196
Oxidative stress in children with beta thalassaemia major : 197
Association of sarcoidosis with haematological malignancies and secondary dysplastic features. A single centre experience : 198
Should we measure TPMT levels before starting azathioprine? : 199
Development of an automated malaria discriminant factor using VCS technology : 200
Voriconazole : first-line therapy replacing liposomal amphotericin B in suspected or proven fungal infection in acute leukaemia patients
Circadian neutropenia unrelated to the intake of psychotropic drugs : 202
Preliminary findings from the web based UKNEQAS Haematology Digital Morphology Pilot Scheme registered for continuing professional development (CPD) with the Institute of Biomedical Science (IBMS) : 203
Monitoring of monoclonal gammopathy of undetermined significance (MGUS) in a large district general hospital : 204
Pre-analytical variables in the measurement of platelet-monocyte aggregates : 205
Use of erythropoietin (Epo) in a district general hospital : adherence to local guidelines
Autoimmune haemolytic anaemia in India : 207
Monitor AC : the development of a web based system for anticoagulant monitoring in hospital and in the community, based on the single shared electronic patient record
Ethnic origin, warfarin dose and VKORC1 mutation in 300 stably warfarinised patients attending Ealing Hospital anticoagulant service : 209
The relationship between ABO blood group and the risk of bleeding during vitamin K antagonist treatment : 210
Non linear dosing of warfarin therapy : implications for Computer Decision Support Software (CDSS)
Patient satisfaction as an anticoagulation service development tool : 212
The influence of hospitalisation on oral anticoagulation control : a population-based study
Response to antiviral therapy in patients with congenital bleeding disorders infected with hepatitis C : 214
Recombinant activated factor VII in the management of major obstetric haemorrhage : 215
Treatment of hepatitis C with peginterferon and ribavarin in adult haemophiliac patients : a single centre experience
Desmopressin reduces circulating platelet monocyte aggregates in patients with von Willebrand disease : 217
The distribution of type 2 von Willebrand disease in the west of Scotland : 218
Fibrinogen concentrate to treat bleeding patients with acquired hypofibrinogenaemia : 219
Patient-determined discontinuation of regular prophylaxis for severe haemophilia : the west of Scotland experience
Can lyophilised plasma be used as quality control material for the ROTEM analyser? : 221
2B or not 2B? A case report : 222
Acute activation of endothelium induces circulation of active von Willebrand factor in HELLP-syndrome : 223
Smoking as a risk factor for venous thrombosis. Results of the MEGA study : 224
Role of the FV Leiden mutation in septic peritonitis assessed in FV Leiden transgenic mice : 225
Protein S-C4BP complex inhibits activated protein C-mediated cleavage of factor Va at R506 but stimulates cleavage at R306 : 226
Current practice of testing for hereditary thrombophilia in the Netherlands : 227
The GOAL study : the impact of factor V Leiden and ABO blood group on pregnancy outcome
High D-dimer level at presentation in patients with venous thrombosis is a marker for malignancy : 229
Predicting risk of recurrent venous thrombosis by fibrin D-dimer : results from a multi-centre prospective observational study
Heterogeneity in tissue-derived pro- and anti-coagulant effects in normal and endotoxaemic-mice : 231
The discriminative value of SHBG, FVII and extrinsic APC resistance with regard to hormonal contraceptives containing androgenic and non-androgenic progestogens : 232
The use of prophylaxis for travel-related venous thrombosis amongst attendees of two international conferences : 233
The risk of deep venous thrombosis associated with an increased endogenous thrombin potential (ETP) : 234
Deletion detection in protein S deficiency : 235
Elevated D-dimer level at presentation in patients with venous thrombosis is a marker for poor survival : 236
Recombinant mini-beta3 integrin fragments for the detection of HPA-1 antibodies : 237
A functional coagulation test to identify anti-beta2 -glycoprotein I dependent lupus anticoagulant : 238
Haplotypes of the fibrinogen gamma gene in ischaemic stroke : a case-control study
ADAMTS13 antibodies in patients with antiphospholipid antibodies : 240
Is impedance plethysmography a useful tool in a systematic screening programme for deep vein thrombosis? : 241
Usefulness of an algorithm consisting of D-dimer level at presentation and clinical evaluation for pretest probability for malignancy in the identification of occult malignancies in patients with venous thrombosis : 242
Severe neonatal thrombosis associated with co-inheritance of type I and type IIb protein C defects : 243
Can the PFA-100 be modified to detect P2Y12 inhibition? : 244
Lupus anticoagulant and anticardiolipin antibody testing identify populations with limited overlap : 245
Seminal tissue factor revisited : 246
A comparison of the VisuLize™ FVIII antigen assay with the COAMATICR FVIII functional assay : 247
NF-kappaB activation determines the cellular response to anti-IgM ligation in chronic lymphocytic leukaemia cells : 248
Sensitisation of B-CLL cells to chlorambucil and fludarabine via inhibition of the DNA damage sensor proteins, DNA-PK and ATM : 249
Applicability of large scale interphase FISH screening in the diagnosis and prognosis of B-cell lymphoproliferative disorders : 250
Low dose intravenous melphalan and bortezomib for relapsed multiple myeloma : 251
Progressive acquisition of additional genetic abnormalities occurs in follicular lymphoma in the absence of morphological transformation : 252
Low dose PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for untreated multiple myeloma : 253
ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia : 254
Schedule dependent effect of bortezomib and melphalan for multiple myeloma associated with changes in Mcl-1 expression : 255
The utility of multicolour immunofluorescence in the identification of a rare subpopulation of B-cells in reactive lymph nodes that may represent the cell of origin of a sub-set of DLBCL : 256
CTD is an effective alternative to CVAMP as induction chemotherapy prior to autologous transplantation for multiple myeloma : a case matched analysis
EBV latent membrane protein 1 induces T regulatory cells in patients with Hodgkin's lymphoma but Th1 cells in patients with EBV driven non-Hodgkin's lymphoma : 258
IgM myeloma : diagnostic utility of plasma cell immunophenotyping and interphase fluorescence in situ hybridisation
CD31 density is inversely related to CD38 expression and predicts for disease outcome in patients with B-cell chronic lymphocytic leukaemia (B-CLL) : 260
The combination of revlimid, dexamethasone and cyclophosphamide is an effective regimen in the treatment of relapsed myeloma : 261
A highly effective model of risk assessment in diffuse large B cell lymphoma (DLBCL) using classification and regression tree (CART) analysis : 262
Dexamethasone, Ifosfamide, Carboplatin and Etoposide (DICarE) with/out Rituximab is an effective regimen for elderly patients with high-grade lymphoma and poor cardiac function : 263
Association of IgVH mutation status and plasma levels of angiogenic activators in chronic lymphocytic leukaemia : Significantly higher bFGF but not VEGF in IgVH mutated patients
Pre-stimulation of myeloma T-cells increases their proliferative response to autologous antigen primed DC and cytolytic activity against myeloma tumour cells : 265
Quality of life in the UK LRF CLL4 trial (on behalf of the UK NCRI CLL Trials Group) : 266
Improved sensitivity for monoclonal gammopathy screening using serum free light chain immunoassays : 267
Early detection of anthracycline cardiotoxicity : 268
Plasma soluble endoglin (sCD105) concentrations in patients with lymphoid malignancies : a pilot study
Efficacy of single-agent bortezomib versus thalidomide in patients with relapsed or refractory multiple myeloma : a systematic review
Molecular characterisation of the variable domains of an alphaIIbbeta3 specific IgM kappa platelet cold agglutinin in a follicular lymphoma patient with treatment refractory thrombocytopenia : evidence of idiotypic overlap with other alphaIIbbeta3 integrin antibodies
Life-threatening motor neurotoxicity with the use of Bortezomib : 272
The effect of IgVH mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukaemia : 273
A case of intravascular large B-cell lymphoma with a complex karyotype including t(3;14), t(2;9) and abnormalities of 6q11 treated successfully with R-CHOP chemotherapy : 274
The favourable prognostic impact of tyrosine kinase domain mutations of FLT3 in AML is related to the level of mutation : 275
ABCG2 is over-expressed on primitive chronic myeloid leukaemia cells and is inhibited by Imatinib Mesylate : 276
Gene expression profiling of AML patients with MLL-PTD identifies differentially regulated members of the HOX gene family : 277
A population-based survey of incidence and outcome of myelodysplastic syndromes in 779 patients from the South Thames area : 278
Addition of cytarabine does not improve upon molecular responses achieved by imatinib alone in chronic myeloid leukaemia : 279
Bcl-2 short interfering RNA enhances the sensitivity of HL-60 cells to cytosine-arabinoside : 280
Five serum biomarkers distinguish Ph + CML from normal and reactive neutrophilia : 281
Enhanced eradication of CML stem cells in vitro using pulsed G-CSF with imatinib mesylate : rationale for a clinical study
Translocation t(8;16) in therapy related acute myeloid leukaemia : 283
Growth factor stimulants improve cytogenetic analysis of chronic myeloproliferative disorders without affecting in vitro cell lineage and cell clones propagation : 284
Acute myeloid leukaemia (AML) in south and west England 2004 : follow up audit in 18 haematology units
Antifungal therapy in haematology patients : 2 year audit in Medway Maritime Hospital
AML associated with the 3q21–26 abnormality, monosomy 7 and diabetes insipidus : 287
Improved disease free survival following non-myeloablative allogeneic stem cell transplantation compared with autologous transplantation in poor risk follicular lymphoma : 288
Measurement of Langerhans cell chimerism in sex-matched haematopoietic stem cell transplant patients using PCR-based genotyping : 289
Dermal dendritic cells but not Langerhans cells stimulate lymphocytes in an in vitro model of cutaneous graft-versus-host disease : 290
Use of a human model to demonstrate selective down regulation of alloreactivity by extracorporeal phototherapy : 291
Observation-based early warning scores to detect impending critical illness predicts in-hospital and overall survival in patients undergoing allogeneic stem cell transplantation (Allo-SCT) : 292
Outcomes of high risk leukaemia and lymphoma patients undergoing reduced intensity conditioned allogeneic transplants (RITs) : 293
Clinical scale ex vivo culture and expansion of BM derived human mesenchymal stem cells : 294
Natural killer T-cells express CD52 : implications for allogeneic stem cell transplantation
Infliximab for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in allogeneic stem cell transplant patients : 296
Use of patient group direction (PGD) by anticoagulant specialist nurses (ASN) for assessment and administration of first dose LMWH for outpatients presenting with suspected DVT : 297
The successful establishment of an anticoagulation service provided by a general practice in the community : the West Suffolk Hospital experience
Long term follow up of leukaemia patients : 299
Decision making processes of patients when asked to participate in a Haematology Phase III cancer clinical trial : 300
Guidelines for TPE in the bone marrow transplant and non-transplant setting : 301
Nursing involvement in CPR decisions within haematology : 302
Side effects of chemotherapy : hints and tips for nurses new to the administration of chemotherapy
The role of the Haematology Outreach Nurse at the James Cook University Hospital, Middlesbrough : 304
Sickle cell care pathways : 305
Evaluation of the PFA-100 as a screening test for haemostatic defects in children : 306
A comparative study of home and hospital monitoring of the INR in children on long term anticoagulation with warfarin : 307
Lupus-anticoagulant-hypoprothrombinaemia syndrome (LAHS) : report of two cases
Audit of the clinical indications for PFA testing in children : 309
The implementation of a home monitoring training programme for children on long-term warfarin : a single paediatric centre's experience
Factor XIII deficiency misdiagnosed as non-accidental injury : 311
Antithymocyteglobulin plus ciclosporin in children less than 12 years with acquired aplastic anaemia : 312
Uptake of a blood transfusion e-learning package amongst F1 trainees (PRHOs) : 313
Fresh-frozen plasma (FFP) quality assessed by dynamics of the clotting process : 314
Low rate of use of transfusion-associated graft-versus-host disease warnings in patients receiving purine analogues : 315
Nitric oxide consumption and pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria : 316
Simple and rapid newborn sickle screening using electrospray mass spectrometry (MS) : 317
The spectrum of molecular defects in idiopathic erythrocytosis : 318
A randomised controlled trial of patient controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease : 319
Is routine molecular screening for common alpha thalassaemia deletions necessary as part of an antenatal screening programme? : 320
Routine antenatal haemoglobinopathy screening in a low prevalence area using microcolumn chromatography : 321
First year of universal neonatal and antenatal haemoglobinopathy screening : service delivery, outcomes and future requirements